The abstract is read at the publisher; the summary is JClub's.
In adults with serious mental illness, initiating GLP-1 receptor agonists was linked to lower 4-year all-cause mortality than initiating SGLT2 inhibitors (4.91% vs 6.45%; HR 0.76).
- Why it matters: Bipolar disorder, major depressive disorder, and schizophrenia carry excess cardiovascular-related deaths, and clinicians need evidence on which glucose-lowering strategy may reduce that risk.
- What they did: Using a retrospective target trial emulation in TriNetX, adults initiating a GLP-1 RA or an SGLT2 inhibitor were matched by propensity scores, then followed for 1, 4, and 10 years.
- The result: In the SMI cohort, the 1-year mortality was also lower with GLP-1 RA initiation (1.46% vs 2.84%; RR 0.52), and semaglutide showed lower 3-point MACE risks in SMI with type 2 diabetes.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.